Revlimid: New Weapon Against Lymphoma

Thursday, 06 Jun 2013 11:35 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Celgene Corp said that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine.

The U.S. Food and Drug Administration approved Revlimid to treat mantle cell lymphoma (MCL) - a type of non-Hodgkin's lymphoma - that has relapsed or progressed following two prior treatment regimens, one of which must include Takeda Pharmaceutical Co's Velcade.
 
"There remains a tremendous unmet need for patients with previously treated mantle cell lymphoma," Dr. Andre Goy, chairman and director and chief of lymphoma at the John Theurer Cancer Center in Hackensack, New Jersey, said in a statement.
 
Revlimid, which will be the first oral treatment for MCL, is already approved to treat multiple myeloma and the blood disorder myelodysplastic syndromes.
 
The medicine had sales of $1 billion in the first quarter for the U.S. biotechnology company.
Despite the unmet need cited by doctors, analysts predicted only a modest revenue boost for Revlimid from the new indication. Cowen and Co analyst Eric Schmidt forecast additional annual sales of about $100 million to $200 million from the additional approval, saying it was not likely to provide a boost to Celgene's shares.
 
MCL accounts for about 6 percent to 7 percent of total non-Hodgkin's lymphoma cases, or about 11,000 cases, the company said.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Help For Ragweed Allergy

Thursday, 17 Apr 2014 16:02 PM

The U.S. Food and Drug Administration has approved Merck Co's pollen allergy drug Ragwitek. The tablet, which is admi . . .

Once-a-Week Diabetes Drug

Tuesday, 15 Apr 2014 12:10 PM

The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 d . . .

Grass Allergy Pill a First for US Sufferers

Wednesday, 02 Apr 2014 07:05 AM

France's Stallergenes has received U.S. regulatory approval to sell the first immunotherapy pill against grass allergies . . .

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved